The numbers of mast cellsimm2 of lung parenchyma were counted in four controls, 15 cases of primary plexogenic pulmonary arteriopathy (PPA), and 17 cases in which the arteriopathy was secondary to congenital heart disease, to determine if increased numbers occur in PPA and with what stage of disease they might be associated. Considerable accumulations of lung mast cells may occur in this disease, but these are not closely related to any particular histological stage in the development of the arteriopathy.
Much has been written on the pathology of plexogenic pulmonary arteriopathy (PPA), but until recently this has been restricted almost entirely to a consideration of the histopathology or ultrastructure of the pulmonary blood vessels. In fact, a wide range of histological changes develops in the lung substance in this disease including alveolar macrophages and siderophages, cholesterol granulomas, lymphoid tissue and periarterial lymphocytes. ' Other parenchymal lesions found include haemorrhages, prominence of granular pneumonocytes, early pulmonary fibrosis, dystrophic calcification, metaplastic bone formation and the appearance of cells resembling meningocytes around pulmonary venules.' Increased numbers of pulmonary endocrine cells containing gastrin-releasing peptide and calcitonin appear in the bronchiolar epithelium and alveolar walls and are related to the stage reached in the development of plexogenic pulmonary arteriopathy.2 These neuroendocrine cells are most numerous-and prominent when the plexiform lesions are large and cellular, and in the pre-plexiform stage when muscle cells are migrating from the media into the intima.
Mast cells characteristically accumulate in the lung parenchyma in conditions of pulmonary arterial with capillary hypertension such as is found in mitral stenosis3 and following the administration of pyrrolizidine alkaloids.4 A similar accumulation also occurs in animals subjected to hypoxia in experimental conditions in the laboratory' or on exposure to the hypobaric hypoxia of natural high altitude. 6 Methods Thirty six cases were studied. Four (cases [1] [2] [3] [4] in the age range 21-29 years were controls, three of whom had died in road accidents. Seventeen (cases 5-21) , in the age range 6-39 years, were patients with PPA secondary to various forms of congenital cardiac septal defect (table 1) . The remaining 15 (cases 22-36), in the age range 4-46 years, were patients with primary plexogenic pulmonary arteriopathy (table) . Cases of the arteriopathy which may, rarely, be associated with cirrhosis of the liver or portal vein thrombosis were not available for study.
The lungs became available at combined heart and lung transplantation. In each case a slice of lung fixed in 10% formalin was received in the laboratory. Under ideal conditions, such as might be obtained in animal experiments, the lungs would have been distended with fixative until the pleural surfaces were smooth, to allow accurate determination of the absolute numbers of mast cells present. The fixative of choice would have been methanol because human mast cell granules are slightly soluble in aqueous solutions offormaldehyde. To take the opportunity of studying this unusual pulmonary tissue at surgery, however, it was necessary to accept less than ideal conditions of distension and fixation. As all the specimens were processed in the same way it was thought that the results of quantitation were valid for purposes of comparison, although the absolute numbers might be marginally smaller than if fixed in methanol. Three blocks of the slice of lung from each patient were used for this study.
Paraffin wax sections of 5 um in thickness were stained with a solution of 2% toluidine blue in 5% aluminium sulphate which is a highly specific stain for the detection of sulphated mucopolysaccharides in tissue sections. 
Code: C = cellular plexiform lesions; S = small and sparse plexiform lesions; P = preplexiform lesions; M = mature plexiform lesions.
tissue mast cells, they require prolonged staining with toluidine blue for up to a week to become apparent. Such a problem is unlikely to have vitiated the results of the present investigation because so far as the authors are aware there have been no reports to suggest that different mast cell subpopulations are associated with human pulmonary vascular disease. Certainly in other human organs, such as the uterus, the heterogeneity of histological properties of mast cells is more likely to reflect their functional state than a subpopulation.9
The sections of lungs were systematically scanned and mast cell counts made using an eyepiece graticule that had been calibrated with a stage micrometer. The squared graticule, itself subdivided into 100 small squares, was used on 20 areas of lung so that the mast cell content of 2000 small squares was counted in each case (fig 1) . As a consequence the density of mast cells/mm2 of the histological sections of lung was calculated. The area of one of the squares was 2-37 x 10-3/mm2 so that the total area of lung studied in each case was 4.74/mm2.
In each case the stage of PPA reached was recorded. The term "plexogenic" implies that the disease has the potential for forming plexiform lesions but that they need not be present for the diagnosis to be made. In the preplexiform stage there was migration of vascular smooth muscle cells into the intima where they had undergone transformation into myofibroblasts which occluded small pulmon- show an accumulation of mast cells in the lung.4 In the control cases scanty mast cells were This suggested to us that the increased numfound scattered diffusely or in small focal bers of mast cells represent a reaction to the collections within the perivascular and sub-proliferative lesions which develop in the lungs pleural connective tissues of the lung. In the of rats secondary to the terminal onset of cases of PPA mast cells were also found in these congestive cardiac failure with pulmonary sites but in greater profusion (fig 2) . They also capillary hypertension. We found the mean commonly extended into the secondary con-mast cell count in 22 control animals to be nective tissue septa of the lung and in the walls 3/mm2; the mean count in 21 test rats was of bronchioles. Most importantly, however, 78/mM2. The intimal fibromuscular pads, they were found extensively throughout the which are a normal feature of the pulmonary lung parenchyma. Even here, however, they veins of the rat, are thickened in animals which were more numerous in the adventitia of small have died of congestive heart failure after pulmonary blood vessels.
ingesting Crotalaria spectabilis seeds. Contraction of this muscle in the pulmonary veins QUANTITATIVE might impede blood flow and result in the The numbers of mast cells/mm2 of lung paren-development initially of pulmonary venous and chyma are shown in the table. Considerable capillary hypertension with exudative lesions numbers of mast cells were found in both in the lung parenchyma and the accumulation primary PPA and in the form secondary to of mast cells. congenital heart disease. In the primary form Subsequently, it has been shown that mast the numbers ranged widely from 8 4-113.8/ cells in the lung are not confined to the developmm2 with a mean value of 57.3/mm2 (SD 29-0). ment of pulmonary arterial hypertension when In the secondary form there was also a wide this is associated with capillary hypertension range from 1 1-113 8/mm2 with a mean value and brown induration alone. It is now well of 51.4/mm2 (SD 38 6). For eight cases with established that mast cells are in some way sparse numbers of plexiform lesions the range related to the development of muscle in the was 8 4-113.8/mm2 and the mean 44.3/mm2. In peripheral portion of the pulmonary arterial 17 cases with cellular plexiform lesions the tree which occurs in the presence of sustained range was 5*9-113 8mm2 and the mean was alveolar hypoxia. It is not certain, however, 59-0/mm2 (SD 33-1). In three cases with whether the mast cells act as agents in initiating mature plexiform lesions the range was 1 1-constriction of the small pulmonary arterial 47.9/mm2 with a mean of 21.4/mm2. In four vessels or in relaxing them. Mast cells contain cases in the preplexiform stage of the several vasoactive substances, including 5-arteriopathy the range was 58 2-106 7/mm2 hydroxytryptamine and histamine." From the with a mean of 77.9/mm2. outset the evidence suggested that the former is not involved in the hypoxic response.'415
Gradually the concept developed that alveolar Discussion hypoxia causes mast cells to liberate the hisAt the end of the last century Ehrlich and tamine that induced pulmonary vasoconstricWestphal made the original observations that tion. Some authors found that histamine was mast cells abound in the "brown induration" of released from animals' lungs during hythe lung, according to Riley.'0 In a previous poxia,'6 7 but no direct transmission of investigation we confirmed these classic vasoconstriction was shown when the effluent observations by quantitative studies which of a hypoxic lung was passed through a second showed that the number of mast cells rose from lung. Hypoxia has been shown to cause in vitro Heath, Yacoyb release of histamine from peritoneal mast cells in rats." The treatment of dogs with disodium cromoglycate, which prevents the release of histamine from mast cells, has prevented hypoxic pulmonary vasoconstriction. In one experiment the mast cell density doubled in the lungs of eight rats exposed for 20 days to a diminished barometric pressure of 380 mm Hg, simulating an altitude of 5500 metres.5 Up to that time everyone seemed to support the idea that an accumulation of mast cells in the lung brings about an increased secretion ofhistamine and pulmonary vasoconstriction.
Although it is easy to show a temporary accumulation of mast cells in the lung under conditions of simulated high altitude, however, it is far more difficult to come to any conclusion as to what function they are fulfilling. The studies of Mungall showed that when rats were exposed to hypoxia, mast cells did not accumulate until after 21 days of exposure, but right ventricular hypertrophy was apparent after only 14 days, a rather unlikely event if the mast cells were instrumental in raising pulmonary vascular resistance leading to right ventricular hypertrophy.
" A major difficulty in accepting histamine from mast cells as the mediator of hypoxic pulmonary vasoconstriction is that its effect on the pulmonary circulation has not universally been shown to be constrictor. ' We have recently pointed out that the basis for the increased pulmonary vascular resistance in PPA is twofold-namely, constriction of small pulmonary arteries, and occlusion of these vessels and of pulmonary arterioles by myofibroblasts in the lumen resulting from migration of smooth muscle cells from the media into the intima.' Mast cells are most unlikely to be involved in this migration of muscle cells but they could affect the tone ofthe pulmonary arterial vessels in the direction of vasodilatation.
In the last century Ehrlich made his classic observation that his newly discovered mast cells were found prominently in the lung in brown induration with chronic pulmonary oedema and early fibrosis. Such widespread parenchymal changes are found in the lung in mitral stenosis, chronic left ventricular failure, and poisoning with pyrrolizidine alkoloids, in all of which lung mast cells abound. At high altitude, hypoxic pulmonary hypertension carries with it the ever-present risk of the development of pulmonary oedema2' and mast cells appear in this environment ofa lung prone to the constant danger of exudation into the alveolar spaces. In plexogenic pulmonary arteriopathy a wide variety of parenchymal changes are also found, including alveolar macrophages and siderophages, haemorrhages, prominence of granular pneumonocytes, fibrosis of alveolar walls, dystrophic calcification and osseous nodules. It may well be that the accumulations of mast cells in the lung in PPA are thus but part of these parenchymal changes, just as Ehrlich found them to be so with the brown induration of mitral stenosis.
